Home › Interstitial Lung Diseases › Ohio
Interstitial Lung Diseases clinical trials in Ohio
14 studies for Interstitial Lung Diseases are looking for participants at sites in Ohio.
Cities in Ohio
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- University of Cincinnati Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine, Cincinnati
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 29, 2026 · NCT05798923Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA015, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07179380FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07540988A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Cincinnati
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- University of Cincinnati Medical Center, Cincinnati
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University Hospitals Cleveland Medical Center, Cleveland
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- University of Cincinnati Medical Center, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- The Cleveland Clinic, Cleveland
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- Ohio State University, Columbus
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Aug 10, 2026 · NCT07175038Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 2
Ages 4 and older · All sexes · Updated Jul 22, 2026 · NCT04925375Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- University of Cincinnati Medical Center, Cincinnati
- St. Luke's Univeristy Health Network-Pulmonary & Critical Care, Cincinnati
- The Ohio State University Wexner Medical CEnter, Columbus
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
- GSK Investigational Site, Columbus
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Jun 22, 2026 · NCT06576271TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
Up to age 24 · All sexes · Updated Jun 22, 2026 · NCT04098445Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 7, 2025 · NCT05892614From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.